Key Dates
Mar 18-19, 2023
Sep 20, 2022
Abstract Submission Deadline
Mar  17, 2023
Online Registration Deadline
Mar 18, 2023
On-site Registration Date

Zhang Zhiyong


TRanslational research of bone tissue engineering --From Proof-of-Concept to Proof-of-Value


Zhang Zhiyong


Translational Research Centre of Regenerative Medicine and 3D Printing Technologies, Guangzhou Medical University.


Professor Zhang Zhiyong received his B.Sc. degree in biology from Xiamen University of China and PhD degree in bioengineering from National University of Singapore in 2009. From 2010 to 2012, he held an adjunct position in Fourth Military Medical University as Associate Professor. In 2012-2016, he worked as Professor and Group Leader in Shanghai Jiao Tong University and National Tissue Engineering Center of China. In 2017, he joined Guangzhou Medical University as the founding director of the Translational Research Centre of Regenerative Medicine and 3D Printing Technologies, which pursue the “Proof-of-Value” translation strategy to promote the fast bench-to-bed translation of regenerative medicine.  Due to his contribution, Professor Zhang has been granted a number of talent scheme program awards including the National "One Thousand Young Talents"(China’s Recruitment Program of Global Experts)Award by the central government of China, “Eastern Scholar” Distinguished Professor award by Shanghai government and the “Outstanding Medical Academic Leader” award by Guangzhou government.


Bone tissue engineering (BTE) strategy provides a promising approach for large bone defect treatment. Despite its first clinical application report in 2001, BTE strategy still stays as a laboratory technique rather than a regular clinical practice, with very limited clinical impact so far. In order to understand the major bottlenecking factors that hinder the fast clinical translation of BTE technology, the development of tissue engineering technology will be compared with computer technology in order to illustrate the influence of “Proof-of-concept (POC)” and “Proof-of-value (POV)” oriented research strategy on the translation of new technology. Generally, it can be regarded as the BTE 1.0 development stage for the past thirty-year’s R&D effort. BTE 1.0 stage is the POC oriented with the goal to prove the scientific feasibility and clinical efficacy and safety of BTE concept. In order to facilitate its wider clinical application and the final translation from a lab technique into a routine clinical therapeutic practice, we believe, in the subsequential BTE 2.0 stage, the focus of our research should be shift from POC to POV, whose mission is to improve and achieve sufficient clinical and commercial value of BTE strategy to replace the current technique. I will discuss and illustrate the Low-Value points of current BTE strategy, such as unavailability off-the-shelf, high cost, complicated manufacturing process and so on and share with you our POV research efforts and thoughts on how to developing facilitating technologies to conquer these problems one by one. We believe, similar to the development of computer industry, the next stage of POV-orientated R&D effort (BTE 2.0 stage) will be the most critical and essential stage in order to boost up the final translation of BTE strategy into the real clinical technique, and facilitate the commercialization and maturation of the new industry of tissue engineering and regenerative medicine.